Home Blog

AmEx, Wells, USB Offers: Get 15% Off CVS (Max $7.50 Back)


Update 11/2/26: Offer is back on Wells Fargo, AmEx, and U.S. Bank through 11/29 or 11/30. The best version is on Wells Fargo at 15% back, up to $7.50 cashback. (hat Celia)

Update 9/14/26: Offer is back on AmEx, Wells Fargo, and U.S. Bank offers for 10% back at CVS, up to $5 cashback. Valid through September 29th or 30th. 

Update 3/13/26: Amex Offer for 10% back, up to $5 this time, valid through 3/29/26. 

Update 12/10/25: Capital One offer expired, amex offer still good

Update 12/2/25: There’s a similar offer from Capital One Offers with card-link for 10% back at CVS in-store, up to $10 back. That one ends on 12/8/25. (ht reader RM)

The Offer

Check your AmEx Offers for the following deal:

  • Get 10% back on in-store purchases at CVS, up to $10 back. Valid for one purchase. Valid through 12/30/25.

Our Verdict

Nice pharmacy savings. Enroll in Rakuten for 2.5% extra in-store cashback. Stack with CVS gift card deals as well. Or you can buy a $100 Amazon gift card or the like from CVS.

Hat tip to DDG

Tata ಕಂಪನಿಗಳ ನಿಜವಾದ ವಾರಸುದಾರ ಇವರೇನಾ? Explained by Angel Investments



Invest in Wint Wealth Bonds:

Investment Help Form:

————————————–

For investments help: 9035254332
For business and collaboration: collab@angelinvestments.co.in
For any questions: ask@angelinvestments.co.in

Visit our website:

Subscribe to Team angel investments channel =

—————————————-
Disclaimer:
This video is created purely for education and awareness.
It does not give any buy/sell/hold recommendations, price targets, intraday levels, or trading signals.
The companies, sectors, economic trends, or financial concepts discussed here are only for learning, not advice.

Angel Investments does not provide any unregistered investment advisory, stock tips, or guaranteed return services.
All investments involve risk. Please consult a SEBI-registered investment adviser or your financial professional before making any investment decisions.

This content is independent, research-based, and shared only to help viewers understand finance, business models, and the stock market in a responsible and compliant manner.

Our Free Course 📚

Basics Of Stock Market of Begginers : • (Free) share market complete course in kan…
Fundametal Analysis Course in Kannada : • (Free) Fundamental Analysis course in Kannada
Mutual Fund Course in Kannada : • mutual funds
Business Analysis in Kannada : • Business Analysis
Learnings From the Greate Investors : • Personalities To Learn
Your doubts and My Answers : • QnA
Insurance Series in Kannada : • Insurance

Our Social Media 📺

Instagram : / angelinvestment. .
YouTube : / @angelinvestments_
——————————————

About The Video

Who actually owns Tata Group? Is it the Tata family, Tata Trusts, Tata Sons, or the chairman? In this video, we uncover the hidden structure behind one of India’s most powerful business groups. From Jamsetji Tata and the creation of Tata Trusts to Ratan Tata, Cyrus Mistry, N. Chandrasekaran and the latest Tata Sons listing debate, we explain where ownership, control and decision-making power actually sit — and how the Tata empire continues even when its most famous leaders are gone.

⚠️ Disclaimer:
This video is for educational purposes only. The views expressed are personal opinions based on publicly available information. Investments are subject to market risks. Past performance does not guarantee future returns.

——————————————-

Gadgets :
Camera 📷 :
Lens :
Mic 🎙 :
Soft box 🔈 :
Light 💡:
RGB :

———————————————–
#Tata #TataGroup #TataSons #TataTrusts #RatanTata #JamsetjiTata #JRDtata #NoelTata #Chandrasekaran #CyrusMistry
#TataHistory #TataStory #TataBusiness #TataEmpire #TataCompanies #TataFamily #TataOwnership #TataStructure #TataGovernance #TataLeadership
#CorporateGovernance #CorporateStructure #CompanyStructure #BusinessStructure #BusinessHistory #IndianBusiness #IndianBusinessHistory #IndianCompanies #IndianConglomerate #CorporateIndia
#BusinessCaseStudy #BusinessStory #BusinessExplained #HowCompaniesWork #CompanyOwnership #Shareholder #ShareholderRights #BoardOfDirectors #BoardMeeting #Chairman
#CEO #Management #IndependentDirectors #CorporateLeadership #HoldingCompany #PromoterCompany #Investment #Investing #InvestorEducation #FundamentalAnalysis
#CompanyAnalysis #BusinessAnalysis #StockMarket #StockMarketIndia #IndianStockMarket #StockMarketEducation #FinancialEducation #FinanceKannada #StockMarketKannada #BusinessKannada
#KannadaFinance #IndianInvestors #LongTermInvesting #WealthCreation #InvestmentEducation #TataSonsListing #TataGroupHistory #AngelInvestments #IndianBusinessStory #BusinessKannada #StockMarket #StockMarketIndia #StockMarketEducation #FundamentalAnalysis #CompanyAnalysis #BusinessAnalysis #Investment #Investing

source

Digital Currencies: Five Questions Every Portfolio Manager Should Ask


This Q&A is gleaned from articles published in Enterprising Investor on this subject within the past 100 days. These articles are linked below. This is designed for CFA charterholders, portfolio managers, wealth advisers, and institutional investors, with an emphasis on what is changing, why it matters, and what practitioners should do next.

Stablecoins, CBDCs, and the changing infrastructure of global finance.

Montreal looks to streamline approvals using standardized housing plans




The city is working with its boroughs to adapt federal catalogue designs to local rules, although projects would still require site-specific review and approval.

The Best Dividend Stocks to Buy With $5,000 in November


Over the past year, many dividend stocks lost their luster for two reasons. First, higher-growth AI stocks continuously pulled investors away from conservative income stocks. Second, the Fed’s rate hike in September — its first in three years — drove up the yields of safer fixed-income investments and made them more attractive than blue chip dividend stocks.

That pressure might persist through the end of the year, but it’s creating attractive buying opportunities for income investors who plan to hold their dividend stocks for the long term. Let’s look at three dividend stocks that are worth buying with $5,000 (or more) in November: AbbVie (ABBV -2.10%), Johnson & Johnson (JNJ -1.51%), and Medtronic (MDT +1.93%).

Image source: Getty Images.

AbbVie

AbbVie, one of the world’s largest pharmaceutical companies, has raised its dividend annually for 53 consecutive years. That makes it a Dividend King, or a company that has continuously raised its payout for at least 50 consecutive years.

AbbVie’s forward yield of 2.4% might seem low compared to the 10-Year Treasury’s 4.9% yield. However, it still has ample room for future hikes, since it spent only two-thirds of its free cash flow (FCF) on dividends over the past 12 months. It’s also generated a total return of 199% over the past five years, easily beating the S&P 500‘s (^GSPC +0.54%) total return of 77%.

ABBV AbbVie

$288.70-$6.19 (-2.10%)

NYSE · As of 12:17 PM ET 11/02/26

Past performance never guarantees future gains, but AbbVie’s future still looks bright. Over the past few years, it has offset the loss of U.S. exclusivity for Humira, its blockbuster autoimmune drug, by acquiring companies (including Allergan, ImmunoGen, and Cerevel) and ramping up sales of two new immunology drugs, Skyrizi and Rinvoq.

From 2025 to 2028, analysts expect AbbVie’s adjusted EPS to grow at a 22% CAGR. Those are impressive growth rates for a stock that trades at 18 times next year’s earnings.

Johnson & Johnson

Johnson & Johnson is another Dividend King that has raised its payout for 64 consecutive years. It pays only a 2% forward yield, but it spent just 64% of its FCF on dividends over the past 12 months. It also delivered a total return of 89% over the past five years.

Over the past several years, J&J streamlined its massive business by divesting its slower-growth divisions. Today, it operates two main businesses: Innovative Medicine, which sells pharmaceutical products; and MedTech, which sells medical devices.

JNJ Johnson & Johnson

$269.09-$4.12 (-1.51%)

NYSE · As of 12:19 PM ET 11/02/26

The Innovative Medicine segment drives most of its growth, and it’s been ramping up its production of new drugs — including Tremfya for autoimmune disorders and Icotye for psoriasis — to offset its loss of U.S. patent exclusivity for Stelara, its blockbuster psoriasis drug. It also owns a diverse portfolio of patent-protected cancer, autoimmune, and cardiopulmonary drugs.

From 2025 to 2028, analysts expect J&J’s adjusted EPS to grow at a 9% CAGR. It’s still reasonably valued at 25 times next year’s earnings, and should remain a popular defensive stock to hold if the broader market pulls back.

Medtronic

Medtronic, one of the world’s top medical device makers, has raised its dividend for 49 consecutive years and is on track to become a Dividend King next year. It pays a forward yield of 3%, and its dividends only consumed 60% of its FCF over the past 12 months.

MDT Medtronic

$98.40+$1.86 (+1.93%)

NYSE · As of 12:16 PM ET 11/02/26

But over the past five years, Medtronic delivered a negative total return of 5%. Without reinvested dividends, its stock price fell 19%. It struggled with supply chain constraints, inflation, forex headwinds, an uneven recovery in elective procedures post-pandemic, and regulatory challenges in its diabetes unit. It also grappled with quality-control issues and the growing use of GLP-1 drugs, which could throttle demand for certain medical procedures.

However, Medtronic’s future looks a lot brighter. Over the past two fiscal years (which ended in April), its earnings grew again as its component costs normalized, it expanded its higher-growth cardiovascular businesses, and it spun off its diabetes unit as MiniMed (MMED +2.82%).

From fiscal 2026 to fiscal 2029, analysts expect its adjusted EPS to grow at an 8% CAGR. Its stock still looks like a bargain at 15 times next year’s earnings, and it should attract more attention once more investors realize it’s overcoming its previous challenges.

Successful but Unfulfilled: What Physicians Should Ask Before Taking the Next Promotion



Years ago, I had what I thought was my dream job. I loved the people I worked with. I loved what I was doing.

But if I’m honest with you, that by itself wasn’t enough.

I’ve been thinking about that a lot lately, because I keep hearing a version of it from other physicians. Department chairs. Section chiefs. People who, from the outside, have everything they worked for.

Some of them have the next job on the table. A bigger title at another institution, which means uprooting themselves and their family and moving to a new city. The question they ask me isn’t whether they can get it. They know they can. The question is whether it would be worth it. Whether they’d actually be any happier.

If you’re successful but unfulfilled, you’re not ungrateful, and you’re not the only one. Below is why it happens, what the research says actually makes people happy, and the questions I’d ask before taking the next step up.

Disclaimer: This article is for informational and educational purposes only and does not constitute financial, legal, or investment advice. Any investment involves risk, and you should consult your financial advisor, attorney, or CPA before making any investment decisions. Past performance is not indicative of future results. The author and associated entities disclaim any liability for loss incurred as a result of the use of this material or its content.

It’s not just the talks. Or the speakers. Or the strategies.

PIMDCON, the #1 Real Estate & Entrepreneurship Conference for Physicians, works because of what happens between the sessions.

The conversations. The clarity. The shift.

LEARN MORE ABOUT PIMDCON

Why do successful physicians feel unfulfilled?

Most successful physicians who feel unfulfilled aren’t burned out. They finished the climb they were trained for, and nothing took its place.

Think about how we got here. Somebody handed us a path. Get the grades. Get into med school, then residency, then fellowship. Become an attending. Make partner or get promoted. Run the section. Run the department.

Every rung had a next rung, clearly labeled. Nobody along the way stopped and asked, and then what?

So we climbed, and we got very good at it. That’s what the system selects for: people who can keep their head down and keep moving toward the next thing for twenty years. Somewhere in there, climbing stops being something you do and becomes who you are.

Then one day the ladder ends. You’re the chair. You’re the chief. There’s no obvious next rung, or the next one looks a lot like the one you’re standing on. And it gets quiet.

That flatness is not a character flaw, and it’s not ingratitude. You can be deeply grateful for your life and still feel it. It’s what happens when the goal was the climb itself.

I’ve written before about the arrival fallacy, the belief that I’ll be happy when I get there. This is the next chapter of that. It isn’t “I’ll be happy when.” It’s “I’m here. Now what?”

Is this a midlife crisis?

Partly, yes. And that isn’t an insult.

We turned the midlife crisis into a punchline. The guy who buys the sports car. The one who blows up his marriage. So nobody wants to admit they might be in one. But the pattern underneath it is real, and it isn’t just men. Women go through it too.

The research is surprisingly consistent. Economist David Blanchflower looked at well-being data from 132 countries and found the same U-shaped curve almost everywhere. Life satisfaction drifts down through early adulthood, bottoms out in midlife, and comes back up. In advanced economies, the low point averaged about age 47 (Blanchflower, NBER 2020).

So if you’re in it, you’re not broken. You’re roughly on schedule.

A few things tend to land at once in your forties and fifties. The career goals you set in your twenties are either done or clearly not going to happen. Your kids need you differently, or they’re about to leave. Your parents need you more. And your own body starts reminding you that you won’t be here forever.

For physicians, it can hit harder. We spent our twenties and a good part of our thirties in training. We told ourselves we’d live later. Then we look up, later is now, and we’re not sure we know how.

The sports car isn’t the crisis. It’s a bad answer to a real question: is this the life I want to spend the rest of my time on?

Will a bigger job make you happier?

Probably not for long, and the research on that is pretty clear.

Psychologists call it hedonic adaptation. We get used to almost every positive change. The raise. The new title. There’s a bump, and within months it becomes your new normal, with a bigger baseline to protect.

The classic example is lottery winners. In one well-known study, people who had won between $50,000 and $1 million were no happier than a comparison group just one to 18 months after winning. Job changes follow the same pattern. Managers who switched jobs got a rise in job satisfaction right after the move, and it faded within about a year. Researchers call those the honeymoon and the hangover (Fritz, Walsh, and Lyubomirsky, 2017).

The chairs and chiefs I talk with have already been through that cycle several times. Each promotion was a bump that faded. There’s no reason to expect the next one to work differently.

And look honestly at what the bigger job usually is. It’s the same job description with more of it. More meetings, more politics, more nights answering email. Less time with patients, which for a lot of these physicians was the part they actually loved. Then there’s the cost to the family: a new school for the kids, a new city for your spouse, and leaving the people who’d show up if something went wrong.

None of this is an argument against ambition. Some people should take the job. They should take it because it serves the life they want, not because it’s the next rung and climbing is the only move anyone ever taught them.

What actually makes people happy?

The best long-term evidence points to one thing above the rest: the quality of your relationships.

The Harvard Study of Adult Development began in 1938 and has followed its participants, and now their children, for more than eight decades. Robert Waldinger, the psychiatrist who directs it, says the strongest predictors of who stayed happy and healthy over a lifetime were the warmth and quality of their relationships (KUNC/NPR interview, 2023). Not how many people they knew. Whether they had people they could call in the middle of the night.

That’s uncomfortable for physicians. Relationships are usually the first thing we cut when work gets busy. We miss the dinner. We miss the game. We tell ourselves we’ll make it up later.

When I put that next to my conversations with these chairs, it clicked. What was missing for them wasn’t competence. These are some of the most capable people I know. What was missing was control over their own time and closeness to the people who matter most. Both had slipped, mostly without them noticing.

A bigger job, at a new institution, in a new city, takes more of both.

Questions to ask before your next career move

In those conversations, we talked about titles, institutions, and comp. We never got to the question that mattered most: what do you actually want your life to look like? Not your career. Your life.

These are the questions I’d ask now. Take your time with them, and write the answers down.

  1. What three or four things matter most to you? Not what should matter. Not what your parents or your program director thought should matter. What actually does.
  2. How much of a normal week goes to those things? Not vacation. A Tuesday. Pick a real Tuesday from last month and look at where the hours went.
  3. How much time do you realistically have left with the people you care about? If your parents are in their seventies and you see them twice a year, that’s not a big number. If your kids are twelve and fifteen, the same math applies.
  4. What would you do with the next five years if the title didn’t matter to anyone? If nobody was keeping score.

If your honest answers point toward the new job, take it, and take it with clear eyes. If they don’t, you have your answer too.


Subscribe to receive the 7 Steps you can follow to achieve Financial Freedom

If financial freedom is your goal, there’s no better time to get started than right now.

Unlock actionable steps that you can take every day to fine-tune your goals, discover your interests, and avoid costly mistakes on your financial freedom journey.


Money is a tool, not the scoreboard

Most of us treat money like the scoreboard without realizing it. It’s a tool for the life you want.

What changed my thinking on this is that the window to actually use it is narrower than we assume. There’s a stretch when you have the health, the energy, the money, and the people, all at the same time. For most physicians, that window is open right now, in their forties and fifties. It closes on a schedule nobody controls.

Bill Perkins makes this case in Die With Zero. The idea that stuck with me is that experiences have a shelf life. The trip you take with your kids at 45 is not the same trip at 75. Your parents may not be around for the second one. Your knees may not be either.

So every year spent climbing toward a rung you’re not sure you want is a year out of that window. That’s the real cost. Not the money. The year.

This isn’t about quitting and going to travel. It’s about deciding on purpose. Take the job if it serves the life. Turn it down if it doesn’t. Just know which one you’re doing.

The best season of my father’s life

My dad was a surgeon. He came to this country after medical school, barely spoke English when he started residency, and built a private practice from nothing. After he retired, he did mission work. By any measure, a full career.

I asked him once when the best time of his life was.

He didn’t have to think about it. He said, “When you kids were still at home.”

He didn’t name the year he built the practice. He didn’t mention a title. It was the stretch when the people he loved were under the same roof, and he was mostly too busy to notice.

I think about that answer a lot, especially when I’m tempted to take on one more thing.

So here’s a question to sit with. If you had to name the best season of your life so far, what was actually in it? Who was there? And is what you’re building right now going to give you more of that, or less?

I talk through this in more depth on episode #340 of the Passive Income MD Podcast. If you’d like more of these conversations, you can join the PIMD newsletter.


Were these helpful in any way? Make sure to sign up for the newsletter and join the Passive Income Docs Facebook Group for more physician-tailored content.

Peter Kim, MD is the founder of Passive Income MD, the creator of Passive Real Estate Academy, and offers weekly education through his Monday podcast, the Passive Income MD Podcast. Join our community at the Passive Income Doc Facebook Group.


Disclaimer: I am not a CPA, attorney, or financial advisor. The information in this post is for educational purposes only and should not be construed as tax, legal, or financial advice. Please consult a qualified professional about your specific situation before making any decisions.

Further Reading



Mercury Business Checking Account Review (2026.11 Update: $500 Offer)